GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...

GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep back to markets around the globe. | As GSK's Blenrep makes its return to ...

GSK (GSK) stock in focus as the FDA staff raise safety concerns over Blenrep combo for multiple myeloma ahead of an AdCom ...

In a recent regulatory development, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug Blenrep, when used in combination with other treatments, may cause eye damage in ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Glaxosmithkline, with multiple operations in Montco, just scored a major regulatory win that could reshape how lupus ...

It was announced last year that work at the GlaxoSmithKline plant in Ulverston would cease, which came to pass at the end of June.

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline ...